A Phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies

Clinical Cancer Research

Volumn 8, Issue 7, 2002, Pages 2142-2148

  Patnaik, Amita ^a   Rowinsky, Eric K ^a   Villalona, Miguel A ^a   Hammond, Lisa A ^a   Britten, Carolyn D ^a   Siu, Lillian L ^a   Goetz, Andrew ^a   Felton, Sally A ^a   Burton, Susan ^b   Valone, Frank H ^b   Eckhardt, S Gail ^a  

^a CTRC Institute for Drug Development   (United States)

^b Titan Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYRIC ACID DERIVATIVE; PIVALOYLOXYMETHYL BUTYRATE; ANTINEOPLASTIC AGENT; PIVALYLOXYMETHYL BUTYRATE; PRODRUG;

ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL DIFFERENTIATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG FORMULATION; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; ERYTHROCYTE; FATIGUE; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; INJECTION SITE; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR; TOXICITY TESTING; VISUAL DISORDER; VOMITING; DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; NEOPLASM; REVIEW; SAFETY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BUTYRATES; CELL DIFFERENTIATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGE; NEOPLASMS; PRODRUGS; SAFETY; SUPPORT, U.S. GOV'T, P.H.S.; HUMANS; MIDDLE AGED;

EID: 0035992310     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Derivatives of butyric acid as potential anti-neoplastic agents
2. Comparison between the effect of butyric acid and its prodrug pivaloyloxymethylbutyrate on histones hyperacetylation in an LH-60 leukemic cell line
3. Rapid alteration of c-myc and c-jun expression in leukemic cells induced to differentiate by a butyric acid prodrug
4. Butyric acid and pivaloyloxymethyl butyrate. AN-9, a novel butyric acid derivative, induce apoptosis in HL-60 cells
5. Histone deacetylase inhibitors as potential anti-skin cancer agents
6. Histone acetylation and cancer
7. Histone deacetylase inhibitors induce programmed cell death in human myeloma cells
8. Mortalization of human promyelocytic leukemia HL-60 cells to be more susceptible to sodium butyrate-induced apoptosis and inhibition of telomerase activity by down-regulation of nucleophosmin/B23
9. c-Myc down-regulation is associated with human colon cell differentiation, apoptosis, and decreased Bcl-2 expression
10. Sodium butyrate induces retinoblastoma protein dephosphorylation, p16 expression and growth arrest of colon cancer cells
11. Redistribution of activated caspase-3 to the nucleus during butyric acid-induced apoptosis
12. Effects of sodium butyrate, a new pharmacological agent, on cells in culture
13. Effect of polar organic compounds on leukemic cells: Butyrate-induced partial remission of acute myelogenous leukemia in a child
14. Butyrate-induced differentiation in leukemic myeloid cells: In vitro and in vivo studies
15. Prodrugs of butyric acid from bench to bedside: Synthetic design. Mechanisms of action, and clinical applications
16. Activity of Pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming units
17. Continual reassessment method: A likelihood approach
18. Microscopic method for assaying F cell production: Ultrastructure changes during infancy and in aplastic anemia
19. Increase of fetal hemoglobin and loss of blood group antigen B in a patient with leukemia
20. Anon. Intravenous fat
21. Formic acid poisoning
22. Pivanex activity in refractory non-small cell lung cancer, a Phase II study
23. Fetal hemoglobin induction with butyric acid: Efficacy and toxicity
24. Extended therapy with intravenous arginine butyrate in patients with β-hemoglobinopathies
25. Modifying histones to tame cancer: Clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors
26. A Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors
27. Myers pharmacokinetic study of intravenous phenylacetate in patients with cancer
28. Phase I study of phenylacetate administered twice daily to patients with cancer
29. A Phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies
30. Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia
31. Pivanex represses oncogene expression and sensitizes tumor cells to chemotherapeutic agents